Skip to main content
. Author manuscript; available in PMC: 2016 May 31.
Published in final edited form as: Ann Rheum Dis. 2012 Jun 23;72(6):911–917. doi: 10.1136/annrheumdis-2012-201451

Table 1.

Baseline characteristics for the study population and by baseline osteoarthritis status

Total
population
(n=51 386)
Non-OA
participants
(n=30 977)
OA
participants
(n=20 409)
p Value
Age (years), mean (SD) 68.2 (8.6) 67.5 (8.7) 69.1 (8.6) <0.0001
BMI (kg/m2), mean (SD) 26.9 (5.9) 26.6 (5.7) 27.4 (6.2) <0.0001
Current or past AOM,
excluding oestrogen, n (%)
13 817 (28) 7427 (25) 6390 (32) <0.0001
Current or past oestrogen or
hormone replacement, n (%)
21 929 (43) 12 609 (41) 9320 (46) <0.0001
Region, n (%) <0.0001
  Canada/Australia 6066 (12) 3851 (12) 2215 (11)
  Europe 21 390 (42) 10 890 (35) 10 500 (51)
  USA 23 931 (47) 16 237 (52) 7694 (38)
Falls in past 12 months, n
(%)
<0.0001
  None 31 881 (63) 20 264 (66) 11 617 (57)
  One 11 567 (23) 6781 (22) 4786 (24)
  Two or more 7453 (15) 3609 (12) 3844 (19)
Comorbidities, n (%)
  Asthma 5763 (11) 3015 (9.8) 2748 (14) <0.0001
  Chronic bronchitis or
  emphysema
4254 (8.4) 2048 (6.7) 2206 (11) <0.0001
  Stroke 1926 (3.8) 1089 (3.5) 837 (4.2) <0.001
  Ulcerative colitis or
  Crohn’s disease
964 (1.9) 483 (1.6) 481 (2.4) <0.0001
  Parkinson’s disease 258 (0.5) 119 (0.4) 139 (0.7) <0.0001
  Multiple sclerosis 312 (0.6) 196 (0.6) 116 (0.6) 0.39
  Cancer 7212 (14) 4252 (14) 2960 (15) 0.007
  Diabetes 1764 (3.5) 1064 (3.5) 700 (3.5) 0.99
Prior fracture, n (%) 11 903 (23) 6307 (20) 5596 (27) <0.0001
Risk factors for fracture, n
(%)
  Current cortisone use 1342 (2.7) 558 (1.8) 784 (3.9) <0.0001
  Secondary osteoporosis* 10 031 (20) 5784 (19) 4247 (21) <0.0001
  Alcohol >20 drinks/week 253 (0.5) 154 (0.5) 99 (0.5) 0.85
*

FRAX definition: use of anastrozole, exemestane, or letrozole; diagnosis of colitis, type I diabetes, or menopause before age 45 years.

AOM, antiosteoporosis medication; BMI, body mass index; OA, osteoarthritis; SD, standard deviation.